FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/7se6qLsQoP https://t.co/64wC94hTTq

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/4WMLbcPLOs

Fatigue in SLE An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients. https://t.co/63JVDUwu88 https://t.co/3dPOThMbMD

Can’t attend #EULAR2026? You won’t miss a thing. RheumNow delivers: 📬 Daily summaries 🎥 Interviews 📊 Key data highlights Follow https://t.co/V10S4oVFsv June 3–6. https://t.co/7Xdj94eFu4

Early GI Involvement Predictive of Scleroderma Outcomes Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc). https://t.co/ftz6TeZv5Z https://t.co/Nw3wQ06VTq

NEW FROM ACR: Clinical responses with an IL-23i in patients with active PsA See the efficacy and safety data through ~5 years in the RheumNow poster hall. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/jejeZwo6is https://t.co/fuF3j3eO0S

Immune-Mediated Inflammatory Diseases Following Uveitis A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID). https://t.co/NJI4369ygL https://t.co/6mHK8hYMeG

HCQ: 5 mg/kg/day Is Only the Starting Point HCQ is one of the most important drugs in rheumatology, especially for SLE. It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if https://t.co/Fwr92tuZf2

Does Exercise and Lifestyle Modification Improve RA? Do exercise or lifestyle modifications reduce the risk of getting RA or change those with early RA? A current review and meta-analysis found no studies addressing the benefit in pre-clinical RA, but found evidence that https://t.co/Bvp3Ery5Fg

Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj

Press release of early study of IMVT-1402 (human mAb targeting FcRn) Open-label Rx in 170 active, refractory RA showed ACR 20/50/70 of 73%/54%/36% at wk 16. Next, Responders will do a blinded withdrawl - blinded results to follow. https://t.co/Mzmb3PPvMF https://t.co/oZ99l9VJQU

NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/SlLO35JhvY